News

RPG Life Sciences Limited informed the National Stock Exchange of India Limited and BSE Limited that MUFG Intime India Private Limited, formerly Link Intime India Private Limited, issued a certificate dated October 3, 2026, confirming compliance under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, pertaining to securities received for dematerialisation during the quarter ended September 30, 2026.

RPG Life Sciences Limited informed the National Stock Exchange of India Limited and BSE Limited that the trading window for dealing in securities of the company by designated persons and their immediate relatives will be closed from Thursday, October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending on September 30, 2026.

Net profit of RPG Life Sciences rose 17.00% to Rs 30.76 crore in the quarter ended June 2026 as against Rs 26.29 crore during the previous quarter ended June 2025. Sales rose 15.85% to Rs 195.69 crore in the quarter ended June 2026 as against Rs 168.92 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales195.69168.92 16 OPM %22.1221.00 - PBDT47.3640.57 17 PBT41.4635.43 17 NP30.7626.29 17 Powered by Capital Market - Live News

RPG Life Sciences will hold a meeting of the Board of Directors of the Company on 28 July 2026.

RPG Life Sciences (RPG LS) has partnered with Archerchem Healthcare to launch Naproxen and Esomeprazole combination for the first time in India by strengthening the existing business relationship with Archerchem. Naprosyn ES is a combination of Naproxen and Esomeprazole, designed to deliver effective anti-inflammatory solution along with gastro protection. The combination has been co-developed by Archerchem Healthcare along with its development partner. RPG LS will exclusively market and distribute Naprosyn ES across the country and Archerchem as the exclusive supplier. The product addresses a significant unmet need in patients requiring long-term Nonsteroidal Anti-Inflammatory Drug (NSAID) therapy, particularly those at risk of gastrointestinal complications. The differentiated formulation is expected to improve patient compliance and enable safer long-term pain management, especially among elderly and gastro-sensitive populations.